TERT and glioma: Distinguishing different astrocytoma subtypes based on TERT promoter mutation status could provide a molecular basis for pursuing more intensive treatments, although the present results indicated that high-grade glioma patients harboring the mutations did not respond well to chemo- and radiotherapy.